Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - What's Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $17.96, but opened at $18.71. Dianthus Therapeutics shares last traded at $18.93, with a volume of 94,771 shares.

Analyst Upgrades and Downgrades

A number of analysts have commented on DNTH shares. Robert W. Baird cut their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. William Blair assumed coverage on Dianthus Therapeutics in a research report on Wednesday. They set an "outperform" rating for the company. Wedbush reaffirmed an "outperform" rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reiterated a "buy" rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Stock Up 2.3%

The company's fifty day moving average is $19.01 and its two-hundred day moving average is $20.54.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. The company had revenue of $1.16 million for the quarter, compared to analysts' expectations of $0.81 million. Dianthus Therapeutics had a negative return on equity of 29.26% and a negative net margin of 1,544.23%. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE lifted its position in shares of Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after buying an additional 1,510 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $33,000. BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $59,000. GAMMA Investing LLC lifted its position in Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock valued at $70,000 after acquiring an additional 3,758 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in Dianthus Therapeutics by 273.1% in the fourth quarter. AlphaQuest LLC now owns 4,197 shares of the company's stock valued at $91,000 after acquiring an additional 3,072 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.